MedTrace Logo

Autohypnosis and Cancerology

NCT03429296 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2023-03-07

No results posted yet for this study

Summary

Therapeutical hypnosis is proven to be an effective medical support to chemotherapy: it was shown that it can reduce the pain, anxiety, fatigue felt by the patient.

Yet, hypnosis requires the presence of an hypnotherapist, which is why auto-hypnosis could be an efficient alternative to handle the side effects of chemotherapy.

In this study, colorectal cancer and breast cancer patients are either taught auto-hypnosis or are taken in standard care for their chemotherapy.

The life quality score (QLQC30) assessed during and after chemotherapies will determine if auto-hypnosis is a good medical support in chemotherapies' adverse effects management.

The proven benefices of auto-hypnosis in the handling of the side effects of chemotherapies could improve the quality of life of cancer affected patients.

Conditions

Interventions

OTHER

Autohypnosis learning

Patients are taught how to do auto-hypnosis by an hypnotherapist before all along their chemotherapy.

Sponsors & Collaborators

  • TIMC-IMAG

    collaborator OTHER

  • AG2R La Mondiale

    collaborator OTHER

  • GEFLUC

    collaborator UNKNOWN

  • Espoir Isère Cancer

    collaborator OTHER

  • Groupe Hospitalier Mutualiste de Grenoble

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-23
Primary Completion
2022-01-21
Completion
2022-07-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03429296 on ClinicalTrials.gov